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Taxol, an antineoplastic agent isolated from the Pacific yew, has been demonstrated in three
phase 2 clinical trials to have major activity (30 percent overall response rate) in patients with
ovarian cancer refractory to cisplatin. The major toxicities associated with the agent are
neutropenia (dose-limiting), hypersensitivity reactions, peripheral sensory neuropathy, and
cardiac arrythmias. A recently reported phase 1 trial of the combination ofcisplatin and taxol
has defined acceptable doses for the two-drug combination to be tested against cisplatin and
cyclophosphamide as frontline therapy of advanced ovarian cancer. Taxol has also been
examined for intraperitoneal administration in patients with ovarian cancer, with a major
pharmacokinetic advantage for peritoneal cavity exposure being demonstrated. Unfortunately,
any future development of taxol as an antineoplastic agent in the management of ovarian
cancer will be dependent on the finding of an alternative source of the drug, as the current
method of obtaining taxol from the bark of the Pacific yew provides insufficient quantities for
large-scale clinical use.
INTRODUCTION
Epithelial ovarian cancer is one of the most responsive solid tumors to cytotoxic
chemotherapeutic agents, with approximately 80 percent of patients experiencing
objective responses to cisplatin-based combination regimens [1-5]. In addition,
approximately 40-50 percent of all patients with advanced ovarian cancer will be
found to have no clinical evidence of disease (by physical examination, CT scan) at
the completion of five to six months of therapy. Unfortunately, despite the high
response rate observed, the majority ofwomenwith advanced (stage III/IV) disease
will ultimately suffer a recurrence and die of complications of their malignancy.
Thus, there is a critical need tofind new active antineoplastic agents in the treatment
ofovarian cancer.
Taxol, anatural product obtained from thebarkofthe Pacificyew, Taxusbrevifolia,
has been demonstrated in several clinical trials to possess a remarkable degree of
activity in patients with ovarian cancer resistant to cisplatin [6-8]. In this review, the
basicbiology supporting the use oftaxol as an antineoplastic agent will be presented
briefly, followed by a discussion of the clinical data currently available on the
pharmacology andtoxicityofthe drug, aswell asits efficacyinpatientswith advanced
ovarian cancer.
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EXPERIMENTAL EVALUATION OF THE ACTIVITY AND
TOXICITY OF TAXOL
While a crude extract of the Pacific yew plant was originally demonstrated to
possess antineoplastic activity, itwas not until the 1970s,when taxol was identified as
the active cytotoxic ingredient ofthe preparation, that significant interest developed
in the agent [9]. Taxol has been demonstrated in a number ofexperimental systems,
both in vitro and in vivo, to possess a wide spectrum ofantineoplastic activity [10,11].
Impressive tumor cell kill is observed in non-human hematologic as well as solid
tumors. In addition, the drug has been shown to be cytotoxic to a number ofhuman
tumors implanted into nude mice, including ovarian cancer [12,13].
There has been intense recent interest in the mechanism oftaxol cytotoxicity. The
drug produces a number of effects on neoplastic and normal cells, but its major
mechanism of action appears to be due to its ability to cause stabilization of
microtubules [10]. Microtubules are important in cell division and in several vital
cellular functions, including maintenance of cell shape, motility, and intracellular
transport. Presumably, taxol-induced interferencewith themicrotubule system leads
to disruption ofone ormore ofthese importantcellular activities and subsequent cell
death.
Of considerable interest are two distinct patterns of microtubule bundling which
have been observed in a small group of patients with acute leukemia treated with
taxol [14]. In patients responding to taxol, the bundling, visualized by indirect
immunofluorescence, persisted in the cells even in the absence oftaxol, while in the
resistant patients the microtubular dysfunction was reversible [14]. This observation
supports the importance of stabilization ofmicrotubules as the major mechanism of
taxol-induced cytotoxicity and also suggests that cells able to reverse or prevent the
defect will be resistant to the agent. Finally, if the experience with the indirect
immunofluorescence assayfortaxol activity in acute leukemia canbe confirmed tobe
of value in other tumors, particularly ovarian cancer, this procedure would be a
useful in vitro test to predict the clinical utility of the drug in individual patients. In
addition to its antitumor activity, pre-clinical evaluation of taxol has shown it to be
toxic to thegastrointestinal tract, bone marrow, and lymphocytes [10]. Thesefindings
were not surprising, as the affected tissues are composed of rapidly dividing cells,
which are most susceptible to the commonly used antineoplastic drugs. Taxol was,
however, also associated with unique side effects not observed with other agents. As
the drug is poorly soluble in water, it was necessary to formulate the drug in
cremophor (polyoxyethylated castor oil) [15]. In dogs, this vehicle can produce
profound reactions, including vasodilation, hypotension, and death, presumably
secondary to a hypersensitivity reaction [10,15]. Thus, it is not surprising, as will be
discussed later, that the clinical administration of taxol in cremophor can be
associated with severe hypersensitivity reactions [16].
PHASE 1 CLINICAL TRIALS OF INTRAVENOUS TAXOL
Taxol has been administered by a variety of schedules in almost a dozen phase 1
clinical trials [17-25]. Therapy has ranged from as rapid an intravenous infusion as a
single dose delivered over several hours, to as slow an infusion as the same dose
administered over 24 hours [17-25]. While the incidence ofhypersensitivity reactions
appears to be greatest in the series employing rapid infusions, and lowest with the
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24-hour infusions, it is not possible to be certain that the improvement in the toxicity
profile is secondary to the change in the rate ofinfusion or simply to the recognition
of the potential for this toxicity and the institution of measures to prevent the event
(prophylactic treatment with corticosteroids, H-1 and H-2 histamine antagonists)
[16].
The dose-limiting toxicity of taxol has been shown to be the development of
neutropenia [10,17-25]. Most patients experience at least moderate neutropenia
following taxol administration. Severe thromobocytopenia has been uncommonwith
the use of this agent. Additional, less common toxicities observed with the adminis-
tration of taxol include: mucositis (which may only develop with late courses,
suggesting a cumulative dose effect), dysphagia, diarrhea, emesis (usually mild in
severity), alopecia (which may be sudden in onset and can involve all areas of the
body), neurotoxicity, cardiac arrythmias, and hypersensitivity reactions.
The most common taxol-associated neurotoxicity is a peripheral sensory neuropa-
thy, although motor dysfunction has been described [10]. The incidence ofneurotox-
icity appears tobe greatest in patients receiving doses oftaxol > 170mg/M2. There is
no clear relationship between prior cisplatin administration and the development of
a taxol-associated peripheral neuropathy. With very high-dose taxol administration
(> 300 mg/M2), transient myalgias and arthralgias have been described, and at least
one patient has experienced a seizure following taxol administration.
Asymptomaticbradycardia isvery common following taxol administration, but this
transient event does not appear to predict more serious cardiac toxicity [10]. Of
greater concern is the fact that atrioventricular block and ventricular arrythmias,
including ventricular tachycardia, have been observed following infusions of taxol.
While chest pain has also been noted in patients receiving the agent, it is not clear if
such pain is ofcardiacorigin or is rather one form ofa hypersensitivity reaction to the
taxol or its vehicle [16].
As previously noted, hypersensitivity reactions to taxol were common in the early
phase 1 clinical trials [16]. In fact, in the Memorial Sloan-Kettering Cancer Center
trial, this effect ofthe preparation was felt to be the dose-limitingtoxicityofthe agent
[24]. The pattern ofthe clinical reactions observed isclassicfor a type I hypersensitiv-
ity reaction (urticaria, dyspnea, bronchospasm, hypotension). Patients can experi-
ence some or all of the symptoms of hypersensitivity within minutes of their first
exposure to taxol [16]. Thus, it is more likelythat the mechanism ofhypersensitivity is
a direct effect of the preparation itself (taxol or cremophor), causing the release of
histamine, rather than an indirect effect mediated through IgE antibodies. Fortu-
nately, the incidence and severity of allergic reactions appears to be reduced by
pre-treating patients with corticosteroids and histamine blockers [16]. The specific
pre-treatment protocol recommended by the National Cancer Institute for patients
receiving taxol includes: dexamethasone, 20 mg administered orally or intravenously
14 and seven hours prior to taxol delivery; diphenhydramine, 50 mg administered
intravenously 30 minutes prior to taxol; and cimetidine or ranitidine, 300 mg or 50
mg, respectively, administered intravenously 30 minutes prior to taxol.
The maximally tolerated dose of taxol in phase 1 clinical trials was found to be
highly dependent on the extent of pre-treatment prior to taxol administration. In
patients with limited cytotoxic drug exposure, it was possible to deliver 200-225
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mg/m2 of taxol with acceptable marrow toxicity. In contrast, patients with extensive
prior chemotherapywere only able to tolerate 110-170mg/m2 ofthe agent.
The peak plasma concentrations oftaxol in patients following intravenous admin-
istration have been found to range between 2.3-8.1 micromolar with doses of
175-390 mg/M2 [10]. Of interest is the fact that the concentrations observed in the
plasma with intravenous delivery have been shown to be cytotoxic against human
tumor in vitro [22]. Although taxol is extensively protein-bound, it is rapidly cleared
from the plasma. Less than 10 percent of the agent is found in the urine, and the
available data suggest that metabolism, biliary excretion, or tissue binding are
responsible for the removal ofthe drug from the circulation.
In the several phase 1 and limited non-ovarian phase 2 trials, antineoplastic
activity has been observed for taxol in melanoma, leukemia, and non-small cell lung,
gastric, colon, breast, and head and neck cancers [10,26,27]. Phase 2 trials are
currently in progress for a number of tumor types. In addition, phase 1 trials oftaxol
with the colony stimulatingfactors G-CSF and GM-CSF, and a combinationregimen
of taxol with cisplatin, are nearing completion [28].
DEFINITION OF REFRACTORY OVARIAN CANCER
Before turning our attention to a discussion of the activity of taxol in refractory
ovarian cancer, it is important that criteria for patient inclusion in this clinical
groupingbe carefully defined. It has been common in the oncology literature to lump
together into the category of "refractory ovarian cancer" all patients who have
previously received cisplatin (or carboplatin) and who have persistent or recurrent
disease. Thus, papers discussing the results of new drugs or drug combinations in
patients with this clinical entity have reported the activity of the agent(s) in a very
heterogeneous group of individuals.
It is now known that patients who have previously responded to cisplatin or
carboplatin and who have developed recurrent disease may respond a second time to
the agents [29-31]. Several studies have documented that the secondary response
rate is significantly influenced by the duration ofthe treatment-free interval between
the last dose of the frontline platinum treatment and the first dose of the secondary
platinum therapy. For example, in a recent retrospective review of secondary
cisplatin therapy in patients with ovarian cancer at the Memorial Sloan-Kettering
Cancer Center, 25-35 percent of patients with a treatment-free interval offive to 24
months following the completion of the frontline therapy responded to a second
course of cisplatin, while > 75 percent of patients with a treatment-free interval of
more than two years responded [29]. Thus, it is inappropriate to consider a patient
with recurrent ovarian cancer to have "refractory" disease, especially if the individ-
ual has previouslyresponded tocisplatin and the treatment-free interval is at least six
months.
In contrast, patients who have recently received cisplatin and who have persistent
bulky disease (no or minor response to therapy or actual disease progression) are a
far more difficult group to treat. Numerous studies have documented the failure of
second-line therapy in this clinical setting to have a significant effect in terms of
either response rate or survival [1,32,33]. It is this patient population which should
appropriately be classified as having refractory ovarian cancer. The discovery of an
agent with significant antineoplastic activity in this disease setting would be an
important clinical finding.
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INTRAVENOUS TAXOL IN REFRACTORY OVARIAN CANCER
With this background, we now turn to the clinical trials of taxol in patients with
ovarian cancer. In the early phase 1 trials of the agent, antineoplastic activity was
observed in several heavily pre-treated individuals with ovarian cancer [10,17,23].
This finding led to the conduct of several phase 2 trials of taxol in patients with
ovarian cancerwho had previously been treated with cisplatin-based therapy.
Investigators at the Johns Hopkins Oncology Center recently reported the results
of a trial of taxol administered as a 24-hour infusion to patients with advanced
ovarian cancer [6]. Doses administered in this trial ranged from 110 to 250 mg/M2.
Treatment was repeated every 22 days, assuming acceptable toxicity and lack of
disease progression. Twelve of 40 (30 percent) evaluable patients responded, with
response durations of three to 15 months. The mean number of chemotherapy
regimens administered to this group of patients prior to the administration of taxol
was 2.7, with the 12 responding patients having received a mean of 3.0 previous
regimens. Thus, this group was a heavily pre-treated patient population. Seven
additional patients had more minor responses (not meeting the criteria for a partial
response), which included clinically relevant improvement in cancer-related symp-
toms.
The toxicity observed in this trial was similar to that reported in the phase 1
studies. Fifty-seven percent of courses were associated with grade 4 (National
Cancer Institute Common Toxicity Scale) leukopenia, the dose-limiting toxicity.
Grade 4 thrombocytopenia was only noted following a single course. While periph-
eral neurotoxicity was common, it was not severe in anypatient.
In a preliminary report, the Gynecologic Oncology Group (GOG) has observed
results similar to the Johns Hopkins trial [7]. Patients were treated with taxol at a
dose of 175 mg/M2, administered as a 24-hour infusion. Treatment was delivered
everythreeweeks, assuming recoveryfrom previous toxiceffectsofthe agent. Among
27 evaluable patients in this studywho had either failed cisplatin therapyorwho had
progressed within six months of completing their frontline chemotherapy program,
eight responses (30 percent) were observed, including two clinically defined com-
plete and six partial responses. Seven responses (50 percent) were noted among the
14 evaluable patients with recurrent disease (treatment-free interval greater than six
months). Dose-limiting toxicity was again found to be leukopenia (65 percent of
coursesassociatedwithwhite blood cell count <2,000/mm3). Severe thrombocytope-
nia (platelet count <50,000/mm3) was observed following 9 percent ofcourses.
Finally, investigators at the Albert Einstein Cancer Center (in New York) and the
Montefiore Medical Center have reported the preliminary results ofaphase 2trial of
taxol, administered at a dose of250mg/M2, as a continuous infusion over 24 hours to
34 patients with advanced measurable ovarian cancer [8]. Thirty of the 34 patients
had previously received cytotoxic chemotherapy. Of the 29 patients evaluable for
response, six (21 percent) achieved either a complete (one patient) or partial (five
patients) response. Twenty patients (59 percent) experienced neutropenic fevers,
while six patients (18 percent) developed significant peripheral neuropathies, which
required a reduction in dose.
In summary, these three clinical trials have firmly established major activity for
taxol in patientswith ovarian cancerrefractory tocisplatin-based therapy. As a result
of the antineoplastic activity demonstrated in patients in the refractory disease
setting, the GOG has initiated a randomized trial oftaxol plus cisplatin compared to
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cyclophosphamide plus cisplatin as initial therapy for patients with advanced bulky
ovarian cancer. While the results ofthis trial will not be available for severalyears, it
is hoped that the addition of an agent active in cisplatin-resistant disease to the
frontline program will increase the overall response rate to therapy, the duration of
responses, and, ultimately, the survival ofindividualswith advanced ovarian cancer.
PHASE 1 TRIAL OF INTRAPERITONEAL TAXOL
Over the past decade, investigators at a number of institutions have explored the
potential for the intraperitoneal administration ofcytotoxic and biological agents as
treatment forpatientswith ovarian cancer [34]. The rationale,pharmacology, unique
toxicities, and efficacy of this approach, using a variety of antineoplastic agents, has
been presented in detail elsewhere and will not be discussed here [34]. With the
demonstrated activity of taxol in patients with advanced ovarian cancer, however, it
was natural that the drug should be examined for its safety, pharmacology, and
potential efficacy when delivered by the intraperitoneal route.
The rationale supporting the intraperitoneal use of taxol is strengthened by
limited experimental data suggesting that the cytotoxicity of the agent against
leukemia cells is related to both the duration of exposure and the concentration of
drug in contact with the malignant cells [14]. With higher drug concentrations and
longer exposure times, there is an increased cytotoxic effect of the agent [14].
Unfortunately, these experiments have not been performedwith solid tumors. Thus,
it is not possible to know for certain ifthe observations madewith leukemiccell lines
are applicable to ovarian cancer cell lines or, most important, to human ovarian
cancer.
In a preliminary analysis of an ongoing phase 1 intraperitoneal taxol trial being
conducted at the Memorial Sloan-Kettering Cancer Center, it has been demon-
strated that the agent can safely be administered into the peritoneal cavity with a
major pharmacokinetic advantage for cavity exposure compared to that of the
systemic compartment [35]. The drug does, however, leave the cavity in significant
concentrations, as grade 3-4 (National Cancer Institute Common Toxicity Scale)
bone marrow suppression has been observed at the highest dose levels tested. The
maximally tolerated intraperitoneal dose of taxol has not as yet been defined, and it
remains uncertain ifthe limiting toxicitywillbe secondary to a local orsystemiceffect
ofthe agent.
CONCLUSION
Taxol has been demonstrated to be a highly active drug in patients with advanced
ovarian cancer. Unfortunately, at the present time, further exploration of the
potential utility ofthis drug in patients with ovarian cancer, or othermalignancies, is
hampered by severe limitations on the supply of the agent. The drug is currently
obtained from the bark of the Pacific yew tree. This method of obtaining taxol
requires that the tree be killed, and the resource is not easily renewed. Taxol has a
complicated structure, and, to date, research has not been able to synthesize the
agent. Thus, efforts have focused on finding an alternative source of the drug from
other trees ofthe Taxus species [36,37] or from cell culture [38]. For example, if the
active drug could be extracted from the needles of the tree, rather than the bark, it
would be possible to obtain the agent without sacrificing the tree. It can reasonably
be hoped that such a source will be found, and that this important agent will
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ultimatelybecome available forgeneral use inpatientswith ovarian cancer and other
malignancies.
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